Breaking News

Clinipace Appoints Medical Director

By Kristin Brooks | February 27, 2014

Schacter to provide strategic guidance for oncology programs

Lee Schacter, Ph.D., MD, FACP, has been appointed executive medical director at Clinipace Worldwide. Dr. Schacter will provide strategic guidance, program design, and medical oversight to clients conducting oncology development programs.
 
Dr. Schacter was previously an independent consultant with Phasen Consulting, and served as acting chief managing officer of the Multiple Myeloma Research Foundation, worked with Janssen R&D, and served as medical director for marketed oncology products at AstraZeneca. Additionally, he served as senior director of global medical affairs at Pfizer and executive medical director, global head oncology, with MDS Pharma Services, among other positions with Yale School of Medicine, Bristol Myers.
 
“Coming off a year of significant growth during which we saw our depth and breadth of expertise managing oncology trials remain one of our strongest core competencies, it was critical for us to expand our team of experts in that field,” said Mark Harvill, chief operating officer, Clinipace Worldwide. “Dr. Schacter is a perfect fit as he comes to us as a highly experienced drug development expert, board certified internist, and medical oncologist with extensive experience in development and regulatory strategy.”

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.